Johnson & Johnson (J&J) has unveiled positive data from its pivotal Phase 2/3 clinical trial, designated as the Energy study,... Read more
J&J eyes rare disease expansion for future blockbuster Imaavy following successful Phase 2/3 anemia trial
12/06/2026
Published by Pharma Biz
